Stereotactic radiosurgery for bone metastases in oligometastatic prostate cancer patients: DESTROY-2 clinical trial subanalysis.

F DeodatoDonato PezzullaS CillaM FerroC RomanoP BonomeM BuwengeA ZamagniL StrigariV ValentiniA G MorgantiG Macchia

Published in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2022)

Data analysis showed few toxicity events, high local control rate and prolonged NEST-FS after linear accelerator-based radiosurgery of bone oligometastases from PCa. The possibility of postponing systemic treatments in patients with oligometastatic PCa by means of SRS should be taken into account. Further prospective studies on larger series are needed to confirm the reported results.

Keyphrases

data analysis
clinical trial
prostate cancer
brain metastases
bone mineral density
oxidative stress
benign prostatic hyperplasia
case control
phase ii
open label
study protocol
small cell lung cancer
double blind
bone loss
phase iii
randomized controlled trial
neural network
oxide nanoparticles
placebo controlled